Cargando…

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study

PURPOSE: To identify the strongest variable(s) linked with the number of ranibizumab injections and outcomes in AURA, and to identify ways to improve outcomes using this association. METHODS: AURA was a large observational study that monitored visual acuity over a 2-year period in patients with neov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holz, F G, Tadayoni, R, Beatty, S, Berger, A R, Cereda, M G, Hykin, P, Staurenghi, G, Wittrup-Jensen, K, Nilsson, J, Kim, K, Sivaprasad, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985685/ https://www.ncbi.nlm.nih.gov/pubmed/27197868 http://dx.doi.org/10.1038/eye.2016.90

Ejemplares similares

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
por: Holz, Frank G, et al.
Publicado: (2015)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD
por: Relton, S. D., et al.
Publicado: (2022)

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
por: Tang, Hin Yan, et al.
Publicado: (2023)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD
por: Relton, SD, et al.
Publicado: (2022)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sivaprasad, Sobha, et al.
Publicado: (2008)

EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study
por: Lai, Timothy Y. Y., et al.
Publicado: (2018)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Predicting Visual Acuity in Patients Treated for AMD
por: Marginean, Beatrice-Andreea, et al.
Publicado: (2022)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography
por: Shen, Mengxi, et al.
Publicado: (2023)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5a125fq5nu2lr5a3dp7s7p52g6